IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v24y2023i8d10.1007_s10198-022-01539-6.html
   My bibliography  Save this article

To what extent does the use of crosswalks instead of EQ-5D value sets impact reimbursement decisions?: a simulation study

Author

Listed:
  • Ângela Jornada Ben

    (Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute)

  • Johanna M. Dongen

    (Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute)

  • Aureliano Paolo Finch

    (EuroQol Office, EuroQol Research Foundation)

  • Mohamed El Alili

    (Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute)

  • Judith E. Bosmans

    (Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute)

Abstract

Purpose Inconsistent results have been found on the impact of using crosswalks versus EQ-5D value sets on reimbursement decisions. We sought to further investigate this issue in a simulation study. Methods Trial-based economic evaluation data were simulated for different conditions (depression, low back pain, osteoarthritis, cancer), severity levels (mild, moderate, severe), and effect sizes (small, medium, large). For all 36 scenarios, utilities were calculated using 3L and 5L value sets and crosswalks (3L to 5L and 5L to 3L crosswalks) for the Netherlands, the United States, and Japan. Utilities, quality-adjusted life years (QALYs), incremental QALYs, incremental cost-effectiveness ratios (ICERs), and probabilities of cost-effectiveness (pCE) obtained from values sets and crosswalks were compared. Results Differences between value sets and crosswalks ranged from −0.33 to 0.13 for utilities, from −0.18 to 0.13 for QALYs, and from −0.01 to 0.08 for incremental QALYs, resulting in different ICERs. For small effect sizes, at a willingness-to-pay of €20,000/QALY, the largest pCE difference was found for moderate cancer between the Japanese 5L value set and 5L to 3L crosswalk (difference = 0.63). For medium effect sizes, the largest difference was found for mild cancer between the Japanese 3L value set and 3L to 5L crosswalk (difference = 0.06). For large effect sizes, the largest difference was found for mild osteoarthritis between the Japanese 3L value set and 3L to 5L crosswalk (difference = 0.08). Conclusion The use of crosswalks instead of EQ-5D value sets can impact cost–utility outcomes to such an extent that this may influence reimbursement decisions.

Suggested Citation

  • Ângela Jornada Ben & Johanna M. Dongen & Aureliano Paolo Finch & Mohamed El Alili & Judith E. Bosmans, 2023. "To what extent does the use of crosswalks instead of EQ-5D value sets impact reimbursement decisions?: a simulation study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(8), pages 1253-1270, November.
  • Handle: RePEc:spr:eujhec:v:24:y:2023:i:8:d:10.1007_s10198-022-01539-6
    DOI: 10.1007/s10198-022-01539-6
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-022-01539-6
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s10198-022-01539-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Brendan Mulhern & Yan Feng & Koonal Shah & Mathieu F. Janssen & Michael Herdman & Ben Hout & Nancy Devlin, 2018. "Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets," PharmacoEconomics, Springer, vol. 36(6), pages 699-713, June.
    2. Hernández-Alava, Mónica & Pudney, Stephen, 2017. "Econometric modelling of multiple self-reports of health states: The switch from EQ-5D-3L to EQ-5D-5L in evaluating drug therapies for rheumatoid arthritis," Journal of Health Economics, Elsevier, vol. 55(C), pages 139-152.
    3. Ines Buchholz & Mathieu F. Janssen & Thomas Kohlmann & You-Shan Feng, 2018. "A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D," PharmacoEconomics, Springer, vol. 36(6), pages 645-661, June.
    4. Mathieu F. Janssen & Gouke J. Bonsel & Nan Luo, 2018. "Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries," PharmacoEconomics, Springer, vol. 36(6), pages 675-697, June.
    5. Ângela Ben & Aureliano Paolo Finch & Johanna M. van Dongen & Maartje de Wit & Susan E.M. van Dijk & Frank J. Snoek & Marcel C. Adriaanse & Maurits W. van Tulder & Judith E. Bosmans, 2020. "Comparing the EQ‐5D‐5L crosswalks and value sets for England, the Netherlands and Spain: Exploring their impact on cost‐utility results," Health Economics, John Wiley & Sons, Ltd., vol. 29(5), pages 640-651, May.
    6. Xinyu Qian & Rachel Lee-Yin Tan & Ling-Hsiang Chuang & Nan Luo, 2020. "Measurement Properties of Commonly Used Generic Preference-Based Measures in East and South-East Asia: A Systematic Review," PharmacoEconomics, Springer, vol. 38(2), pages 159-170, February.
    7. Mickael Löthgren & Niklas Zethraeus, 2000. "Definition, interpretation and calculation of cost‐effectiveness acceptability curves," Health Economics, John Wiley & Sons, Ltd., vol. 9(7), pages 623-630, October.
    8. John Brazier & Roberta Ara & Donna Rowen & Helene Chevrou-Severac, 2017. "A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models," PharmacoEconomics, Springer, vol. 35(1), pages 21-31, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Becky Pennington & Monica Hernandez-Alava & Stephen Pudney & Allan Wailoo, 2019. "The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals," PharmacoEconomics, Springer, vol. 37(1), pages 75-84, January.
    2. Hani Dimassi & Soumana C. Nasser & Aline Issa & Sarine S. Adrian & Bassima Hazimeh, 2021. "Health-Related Quality of Life in Patients with Health Conditions in Lebanese Community Setting," IJERPH, MDPI, vol. 18(16), pages 1-12, August.
    3. Guizhi Weng & Yanming Hong & Nan Luo & Clara Mukuria & Jie Jiang & Zhihao Yang & Sha Li, 2023. "Comparing EQ-5D-3L and EQ-5D-5L in measuring the HRQoL burden of 4 health conditions in China," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 197-207, March.
    4. Kamilla Koszorú & Krisztina Hajdu & Valentin Brodszky & Alex Bató & L. Hunor Gergely & Anikó Kovács & Zsuzsanna Beretzky & Miklós Sárdy & Andrea Szegedi & Fanni Rencz, 2023. "Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(1), pages 139-152, February.
    5. Finch, Aureliano Paolo & Mulhern, Brendan, 2022. "Where do measures of health, social care and wellbeing fit within a wider measurement framework? Implications for the measurement of quality of life and the identification of bolt-ons," Social Science & Medicine, Elsevier, vol. 313(C).
    6. Nancy Devlin & John Brazier & A. Simon Pickard & Elly Stolk, 2018. "3L, 5L, What the L? A NICE Conundrum," PharmacoEconomics, Springer, vol. 36(6), pages 637-640, June.
    7. Lakdawalla, Darius N. & Seabury, Seth A., 2012. "The welfare effects of medical malpractice liability," International Review of Law and Economics, Elsevier, vol. 32(4), pages 356-369.
    8. Theresa Tawiah & Kristian Schultz Hansen & Frank Baiden & Jane Bruce & Mathilda Tivura & Rupert Delimini & Seeba Amengo-Etego & Daniel Chandramohan & Seth Owusu-Agyei & Jayne Webster, 2016. "Cost-Effectiveness Analysis of Test-Based versus Presumptive Treatment of Uncomplicated Malaria in Children under Five Years in an Area of High Transmission in Central Ghana," PLOS ONE, Public Library of Science, vol. 11(10), pages 1-18, October.
    9. Paul Anand & Laurence S. J. Roope & Anthony J. Culyer & Ron Smith, 2020. "Disability and multidimensional quality of life: A capability approach to health status assessment," Health Economics, John Wiley & Sons, Ltd., vol. 29(7), pages 748-765, July.
    10. Elena Olariu & Wael Mohammed & Yemi Oluboyede & Raluca Caplescu & Ileana Gabriela Niculescu-Aron & Marian Sorin Paveliu & Luke Vale, 2023. "EQ-5D-5L: a value set for Romania," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(3), pages 399-412, April.
    11. Nathan S. McClure & Mike Paulden & Arto Ohinmaa & Jeffrey A. Johnson, 2021. "Modifying the quality-adjusted life year calculation to account for meaningful change in health-related quality of life: insights from a pragmatic clinical trial," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1441-1451, December.
    12. Jennifer Prah Ruger & Arbi Ben Abdallah & Craig Luekens & Linda Cottler, 2012. "Cost-Effectiveness of Peer-Delivered Interventions for Cocaine and Alcohol Abuse among Women: A Randomized Controlled Trial," PLOS ONE, Public Library of Science, vol. 7(3), pages 1-12, March.
    13. Osvaldo Ulises Garay & Marie Libérée Nishimwe & Marwân-al-Qays Bousmah & Asmaa Janah & Pierre-Marie Girard & Geneviève Chêne & Laetitia Moinot & Luis Sagaon-Teyssier & Jean-Luc Meynard & Bruno Spire &, 2019. "Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM)," PharmacoEconomics - Open, Springer, vol. 3(4), pages 505-515, December.
    14. Satar Rezaei & Abraha Woldemichael & Sina Ahmadi & Amjad Mohamadi Bolbanabad & Farman Zahir Abdullah & Bakhtiar Piroozi, 2021. "Comparing the properties of the EQ‐5D‐5L and EQ‐5D‐3L in general population in Iran," International Journal of Health Planning and Management, Wiley Blackwell, vol. 36(5), pages 1613-1625, September.
    15. Roberta Ara & John Brazier & Tracey Young, 2017. "Recommended Methods for the Collection of Health State Utility Value Evidence in Clinical Studies," PharmacoEconomics, Springer, vol. 35(1), pages 67-75, December.
    16. Shitong Xie & Jing Wu & Gang Chen, 2024. "Comparative performance and mapping algorithms between EQ-5D-5L and SF-6Dv2 among the Chinese general population," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(1), pages 7-19, February.
    17. Jiaer Lin & Carlos King Ho Wong & Jason Pui Yin Cheung & Prudence Wing Hang Cheung & Nan Luo, 2022. "Psychometric performance of proxy-reported EQ-5D youth version 5-level (EQ-5D-Y-5L) in comparison with three-level (EQ-5D-Y-3L) in children and adolescents with scoliosis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(8), pages 1383-1395, November.
    18. Eliza Kruger & Daniel Aggio & Hayley Freitas & Andrew Lloyd, 2023. "Estimation of Health Utility Scores for Glycogen Storage Disease Type Ia," PharmacoEconomics - Open, Springer, vol. 7(4), pages 627-638, July.
    19. Dirk Müller & Eleanor Pullenayegum & Afschin Gandjour, 2015. "Impact of small study bias on cost-effectiveness acceptability curves and value of information analyses," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(2), pages 219-223, March.
    20. Nancy J. Devlin & Koonal K. Shah & Brendan J. Mulhern & Krystallia Pantiri & Ben van Hout, 2019. "A new method for valuing health: directly eliciting personal utility functions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 257-270, March.

    More about this item

    Keywords

    Quality of life; Methods; Cost–benefit analysis; EQ-5D;
    All these keywords.

    JEL classification:

    • C18 - Mathematical and Quantitative Methods - - Econometric and Statistical Methods and Methodology: General - - - Methodolical Issues: General

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:24:y:2023:i:8:d:10.1007_s10198-022-01539-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.